Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NWBO exhibiting at AACR April 1-5, 2017, Washington D.C.
Walter E. Washington Convention Center
Booth #865 (directly across from Spotlight A)
http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105#.WLljWRSMCqQ
You’re an honorable man; Special Operations Forces would be proud.
Trying to catch up on posts here so if this Argos news has been posted, just disregard:
http://ir.argostherapeutics.com/releasedetail.cfm?releaseid=1008528
Thanks for the link. Interesting story unfolding
Soon-Shiong’s Cancer Moonshot2020 is now called Cancer Breakthroughs2020. Dr. Soon-Shiong’s original initiative was launched the same week Biden’s (Moonshot) initiative to fight cancer was announced causing bit of confusion.
I continue to be perplexed by the role NantWorks (Dr. Soon-Shiong) will play in cancer treatment success. If, indeed, NWBO is going to be a major player in cancer treatment, could NWBO discussions at these high levels be in play thus contributing to this unprecedented silence?
I, for one, do not discount this:
https://www.statnews.com/2017/01/24/trump-patrick-soon-shiong-health-care/
I don’t recall the inclusion of two clinical trials whose sponsors are Asterias Bio and Grifols Therapeutics being listed on NWBO’s website. I may have missed it when I viewed this page in the past. Perhaps I was only focused on GBM
9 studies found for: Northwest Biotherapeutics
https://www.clinicaltrials.gov/ct2/results?term=Northwest+Biotherapeutics&Search=Search
A side bar - Moonshot 2020 has changed their name to Cancer Breakthroughs 2020
Their current newsletter article: Announcing Cancer Breakthroughs 2020?
http://www.cancerbreakthroughs2020.org/cancer-breakthroughs-2020-milestones/
Quote:
“The psychological impact accomplished by the twits that mercilessly attack NWBO and coincidentally its price is outrageous, and I think it even effected/diminished long interpretations regarding the intrinsic value of NWBO if successful.”
As NWBO moves forward to hopeful success, we start to see the walk-backs from these very attackers, twits as you kindly refer to them…or, twackers??
Sadly, their damage has been done.
Perhaps it was offered and a family decision chose differently - who knows.
Make sure you are clicking Investors & Media from the top menu, and then click Press Releases from the drop down
ARGS Point of Interest:
ARGS BOD member: Igor Krol holds an advisory role with Pharmstandard
Have anyone in mind?
Merck - Bristol Myers settlement re Keytruda
http://www.genengnews.com/gen-news-highlights/bms-and-ono-agree-625m-keytruda-patent-litigation-settlement-with-merck/81253750
Amen to that!
You have hair left?
Oops! Too much coffee - trigger happy
Logical points, thank you.
Your post is taking my thoughts off-the-wall here. I was stunned by NW’s remarks recently about his investment in NWBO.
NW is heavily engaged in the UK’s mission to elevate its economic health particularly in the pharmaceutical sector. NW’s involvement is noted in numerous national projects and he is presented as a true British patriot (he is, of course) always stepping up to the plate. Perhaps NW and LP had an agreement/understanding as to an NWBO-Cognate investment in the UK pharmaceutical sector. Could the original NW-LP understanding have been altered due to NWBO and US based pharma collaborations and future possible commitment to Cancer Moonshot 2020.
Just wild speculation on my part as the grape-vine (our MB) attempts to connect dots and feed one another information and conjecture in light of the fact that official information is lacking.
I think NWBO goes into these conferences with as much hope as we have in that the good news will be available. NWBO’s missteps in their timelines to shareholders is evidence that they are not receiving reliable information. Remember - they were late to commit their presence to 2017 Immunology World Conference.
Flipper- click on Chair's Introduction. The title of her presentation was originally on the page with her presentation time but when they changed her time allotment, the subject of her presentation was removed, Perhaps their webmaster was to delete the title, perhaps not.
Quote:
“Then it says 25 minutes for Linda to speak with no title to her talk.”
DCVax® Novel Personalized Immune Therapies for Solid Tumors
Very nice, Mike. Thank you for taking the time to post your very personal experience with Linda Powers.
Recent interview with Aron Thall Senior Director, Global Clinical Lead, Immuno-Oncology, Pfizer (posted on Immuno-World 2017 website)
http://www.immunotherapyforum.com/latest-interviews/interview-with-dr-aron-thall
Home page of the Conference;
http://www.immunotherapyforum.com/welcome
Select AGENDA
Select Thursday, January 19th
Scroll down to time frame 4:30P - right hand column
Hopefully, it takes you there
Quote:
“Hopefully that is meaningful but too many conferences have come and gone without a PR or webcast.”
Agreed, we have had disappointment at some previous conferences; however, I think NWBO was hopeful that “news” could be announced at some of these conferences only to fall back on presentations that didn’t meet shareholders’ expectations.
As for the 2017 Immuno-World Conference, Cognate came in as a Gold Sponsor many months ago taking the primary position and was followed months later by NWBO as an Associate Sponsor taking a secondary position. This may point to NWBO’s caution that a more meaningful presentation may not be sanctioned for release.
Just an observation and opinion only.
Realizing we have all become conspiratorial on this MB, I find this interesting: LP’s presentation position on Immuno World’s agenda has a little revision. The topic of her presentation has been deleted and her presentation time has been extended.
Perhaps changes are being made or another presenter has backed out leaving a time gap to be filled. Reasonable explanations perhaps, but you know how we are here!
http://www.immunotherapyforum.com/immunotherapy-world-2017-agenda
The Blue Ribbon Panel for Cancer Moonshot
Clinical Trials Working Group - Two of the members often cited on this MB
Rick Pazdur, M.D.
U.S. Food and Drug Administration
Mac Cheever, M.D. (NWBO’s SAB)
Fred Hutchinson Cancer Research Center
https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/blue-ribbon-panel-report-2016.pdf
http://www.immunotherapyforum.com/immunotherapy-world-2017-agenda
LP is presenting at 4:30P (right hand column of agenda) on 19th
Conference starts next week. LP on agenda for the 19th.
http://www.immunotherapyforum.com
Thank you John - I now have it as well. I had googled it three times after I first saw it and after I called NWBO and the only response was the IHub message where the NCT # was part of the original msg.
I just placed a call to NWBO to the phone number for clinical trials. I have looked at the clinical trial page prior and about six or seven trials were listed including the ones NWBO had withdrawn. This morning when accessing this link the only trial that comes up is the one we’re all familiar with at UCLA. My call was to inquire if the new trial will be added - that being NCT03014804. Because Jonnson is the stated sponsor, I wasn’t sure it would be listed. I got the impression that the receiver of this call wasn’t quite aware of this web page change and suggested that the page may be undergoing a change.
( 1-2 minutes elapsing here - and, read on)
Oops! I just tried to pull up the trial to check sponsor info and now that NCT trial has disappeared.
Referencing NWBO’s June 13, 2016 PR in regard to new SAB selection:
“Linda Powers, CEO of NW Bio commented: “We are excited to work with such an expert Scientific Advisory Board, and gratified that these leading experts see the encouraging possibilities of the DCVax technology. The SAB members bring diverse and complementary skill sets, in addition to long experience in the field. They will be a valuable resource for the Company, both in the periodic SAB meetings and on an ongoing basis in between the meetings, as we work toward bringing DCVax therapies to patients to help provide much needed new treatment options as soon as possible. In addition, we anticipate that one or more of the SAB members may become involved in our clinical programs.”
Dr. Mac Cheever is on NWBO’s SAB and is noted for clinical trial expertise; his bio in this PR states, “……… he gained extensive experience with design and execution of cancer vaccine clinical trials, FDA related product approval issues and collaboration with major pharmaceutical companies.
Quote:
“Is Forbes with big pharma? why the article doesn't mention anything about dc vax or brain cancer?”
Marzan…
I thought this was a good recap of IO 2016 news. I wouldn’t expect NWBO info in this or similar articles until some news is released by the company or FDA. Part of this article covers Sean Parker’s Cancer Institute and, as we know, some of those funds were directed to UCLA. The formal gala that heralded Parker's newly formed institute and mentioned in this article recognized Dr. Linda Liau and her achievements in immunology. Perhaps that prompted unflattering remarks from some.
Good read - Forbes 28Dec article synopsizing cancer research highlights 2016. Note: one might be amused at the embedded link “drawn some ire": wherein our friend/foe AF is quoted.
http://www.forbes.com/sites/arleneweintraub/2016/12/28/eight-milestones-of-2016-in-the-war-on-cancer/#3fa68f85b336
Maybe there is a "WhistleBlower" component